<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674843</url>
  </required_header>
  <id_info>
    <org_study_id>GAAD-MD-CTP1</org_study_id>
    <nct_id>NCT00674843</nct_id>
  </id_info>
  <brief_title>The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies</brief_title>
  <official_title>Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GAAD Medical Research Institute Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GAAD Medical Research Institute Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are
      characterized by progressive skeletal muscle weakness, defects in muscle proteins and the
      death of muscle cells and tissue. This study will investigate the use of far infrared
      radiation for managing muscular dystrophies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observations from our research studies indicate that, far infrared rays provide energy to the
      body, improve the autonomic functions of the nervous system, restore the functions of the
      endocrine system, strengthen the immune system, improve blood circulation and increase the
      level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain
      cells.

      It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20
      microns, of the central nervous system, the endocrine system and the whole body could
      prevent, control, manage or possibly cure these neuromuscular disorders.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Management and Cure of muscular dystrophies</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation of people with muscular dystrophies</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Muscular Dystrophies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation: Far Infrared Radiation (5μm to 20μm wavelength)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Far Infrared Radiation</intervention_name>
    <description>Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons with muscular dystrophies

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Nedd, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GAAD Medical Research Institute Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Centre for Incurable Diseases</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>August 14, 2009</last_update_submitted>
  <last_update_submitted_qc>August 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kwasi Donyina/Founder and President</name_title>
    <organization>GAAD Medical Research Institute Inc.</organization>
  </responsible_party>
  <keyword>MYOTONIC DYSTROPHY</keyword>
  <keyword>MYOPATHIES</keyword>
  <keyword>Distal Myopathies</keyword>
  <keyword>Muscular Dystrophy, Duchenne</keyword>
  <keyword>Phosphorylase Deficiency (McArdle Disease)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

